An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study.
IT platform
community pharmacies
drug incompatibility
drug interactions
healthcare transitions
information technology
medication recognition
medication reconciliation
oncology
pharmacy
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
20 12 2021
20 12 2021
Historique:
received:
29
06
2021
accepted:
29
10
2021
revised:
21
09
2021
entrez:
21
12
2021
pubmed:
22
12
2021
medline:
28
12
2021
Statut:
epublish
Résumé
Accurate medication reconciliation reduces the risk of drug incompatibilities and adverse events that can occur during transitions in care. Community pharmacies (CPs) are a crucial part of the health care system and could be involved in collecting essential information on conventional and supplementary drugs used at home. The aim of this paper was to establish an alliance between our cancer institute, Istituto Romagnolo per lo Studio dei Tumori (IRST), and CPs, the latter entrusted with the completion of a pharmacological recognition survey. We also aimed to integrate the national information technology (IT) platform of CPs with the electronic medical records of IRST. Cancer patients undergoing antiblastic treatments were invited to select a CP taking part in the study and to complete the pharmacological recognition step. The information collected by the pharmacist was sent to the electronic medical records of IRST through the new IT platform, after which the oncologist performed the reconciliation process. A total of 66 CPs completed surveys for 134 patients. An average of 5.9 drugs per patient was used at home, with 12 or more used in the most advanced age groups. Moreover, 60% (80/134) of the patients used nonconventional products or critical foods. Some potential interactions between nonconventional medications and cancer treatments were reported. In the PROF-1 (Progetto di Rete in Oncologia con le Farmacie di comunità della Romagna) study, an alliance was created between our cancer center and CPs to improve medication reconciliation, and a new integrated IT platform was validated. ClinicalTrials.gov NCT04796142; https://clinicaltrials.gov/ct2/show/NCT04796142.
Sections du résumé
BACKGROUND
Accurate medication reconciliation reduces the risk of drug incompatibilities and adverse events that can occur during transitions in care. Community pharmacies (CPs) are a crucial part of the health care system and could be involved in collecting essential information on conventional and supplementary drugs used at home.
OBJECTIVE
The aim of this paper was to establish an alliance between our cancer institute, Istituto Romagnolo per lo Studio dei Tumori (IRST), and CPs, the latter entrusted with the completion of a pharmacological recognition survey. We also aimed to integrate the national information technology (IT) platform of CPs with the electronic medical records of IRST.
METHODS
Cancer patients undergoing antiblastic treatments were invited to select a CP taking part in the study and to complete the pharmacological recognition step. The information collected by the pharmacist was sent to the electronic medical records of IRST through the new IT platform, after which the oncologist performed the reconciliation process.
RESULTS
A total of 66 CPs completed surveys for 134 patients. An average of 5.9 drugs per patient was used at home, with 12 or more used in the most advanced age groups. Moreover, 60% (80/134) of the patients used nonconventional products or critical foods. Some potential interactions between nonconventional medications and cancer treatments were reported.
CONCLUSIONS
In the PROF-1 (Progetto di Rete in Oncologia con le Farmacie di comunità della Romagna) study, an alliance was created between our cancer center and CPs to improve medication reconciliation, and a new integrated IT platform was validated.
TRIAL REGISTRATION
ClinicalTrials.gov NCT04796142; https://clinicaltrials.gov/ct2/show/NCT04796142.
Identifiants
pubmed: 34932001
pii: v23i12e31321
doi: 10.2196/31321
pmc: PMC8726040
doi:
Banques de données
ClinicalTrials.gov
['NCT04796142']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31321Informations de copyright
©Alessandro Passardi, Patrizia Serra, Caterina Donati, Federica Fiori, Sabrina Prati, Roberto Vespignani, Gabriele Taglioni, Patrizia Farfaneti Ghetti, Giovanni Martinelli, Oriana Nanni, Mattia Altini, Giovanni Luca Frassineti, Martina Vittoria Minguzzi. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 20.12.2021.
Références
J Natl Cancer Inst. 2007 Apr 18;99(8):592-600
pubmed: 17440160
Can Pharm J (Ott). 2016 Dec 07;150(1):24-31
pubmed: 28286590
JAMA Intern Med. 2016 Apr;176(4):473-82
pubmed: 26998708
Ann Intern Med. 2013 Mar 5;158(5 Pt 2):397-403
pubmed: 23460096
Drug Saf. 2020 Jun;43(6):517-537
pubmed: 32125666
Stud Health Technol Inform. 2019;257:70-74
pubmed: 30741175
Int J Health Plann Manage. 2006 Jan-Mar;21(1):75-88
pubmed: 16604850
BMJ Open. 2016 Feb 23;6(2):e010003
pubmed: 26908524
Arch Intern Med. 2012 Jul 23;172(14):1057-69
pubmed: 22733210
Jt Comm J Qual Patient Saf. 2006 Apr;32(4):230-2
pubmed: 16649655
PLoS One. 2018 Jan 12;13(1):e0191028
pubmed: 29329310